OncoMatch/Clinical Trials/NCT07257640
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
Is NCT07257640 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies IL-5 CAR-T cells for hematologic diseases.
Treatment: IL-5 CAR-T cells — This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: IL5RA overexpression (≥50% of leukemic blasts)
Interleukin-5 receptor α (IL-5Rα, CD125) is expressed on ≥50% of leukemic blasts.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy (imatinib, corticosteroids, interferon-α, chemotherapy)
Lab requirements
Liver function
serum total bilirubin ≤1.5 × uln, alt and ast ≤3 × uln
Cardiac function
left ventricular ejection fraction (lvef) >50% as assessed by echocardiography
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07257640 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Does this trial require IL5RA?
Yes, IL5RA overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify